ストックスクリーナーアプリを入手
92.36
2.86%
2.5891
前日終値:
$89.77
開ける：
$91.59
24時間の取引高:
1.03M
Relative Volume:
0.97
時価総額：
$11.48B
収益：
$2.72B
当期純損益:
$254.30M
株価収益率:
44.69
EPS:
2.0665
ネットキャッシュフロー:
$564.37M
1週間 パフォーマンス:
-3.35%
1か月 パフォーマンス:
-13.93%
6か月 パフォーマンス:
-22.26%
1年 パフォーマンス:
-8.37%
1日の値動き範囲:
$90.74
$93.50
1週間の範囲:
$88.53
$97.19
52週間の値動き範囲:
$88.53
$129.50
Revvity Inc Stock (RVTY) Company Profile
RVTY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
92.27 | 11.48B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
431.53 | 166.47B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
192.71 | 135.88B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
420.19 | 32.74B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.59 | 29.40B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.18 | 26.30B | 15.41B | 1.37B | 2.11B | 7.50 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-15 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-07-08 | 開始されました | Leerink Partners | Outperform |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-04 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-19 | 開始されました | Raymond James | Outperform |
| 2023-05-23 | 再開されました | Goldman | Buy |
すべてを表示
Revvity Inc (RVTY) 最新ニュース
Revvity Fuels the Future of Cancer Science with New Research Solutions - Business Wire
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline - Yahoo Finance
Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | RVTY Stock News - GuruFocus
Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com
Revvity price target lowered to $120 from $140 at Bernstein - TipRanks
Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Green Market Report
Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq
What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus
BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus
KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener
Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus
Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener
KeyBanc maintains Overweight rating on Revvity stock at $145 target - Investing.com Australia
KeyBanc maintains Overweight rating on Revvity stock at $145 target By Investing.com - Investing.com South Africa
KeyBanc Adjusts Price Target on Revvity to $145 From $135, Keeps Overweight Rating - MarketScreener
Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price - simplywall.st
Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery - Technology Networks
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Technology Networks
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN
Revvity Q1 2025 Earnings Preview: CEO and CFO to Detail Financial Performance - Stock Titan
FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo - Yahoo
Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus
FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa
What's Going On With Revvity Stock Today? - Benzinga
(RVTY) Investment Analysis - news.stocktradersdaily.com
Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating - MarketScreener
FDA Approves Revvity’s Improved Automated Latent Tuberculosis Test - Medical Product Outsourcing
Revvity gets FDA nod for its automated tuberculosis test (RVTY:NYSE) - Seeking Alpha
Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test - marketscreener.com
FDA greenlights Revvity’s TB diagnostic platform - Investing.com India
Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test - MarketScreener
Game-Changing TB Test: Revvity's New FDA-Approved System Cuts Testing Time by 70% - Stock Titan
Pictet Asset Management Holding SA Has $125.17 Million Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Is Revvity Stock Underperforming the Nasdaq? - MSN
High Content Screening/Imaging Technology Analysis and Global Market Forecasts 2025-2029 with Danaher, Revvity, Thermo Fischer Scientific, Agilent Technologies and Yokogawa LeadingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Revvity Stock Underperforming The Nasdaq? - Barchart.com
Is Revvity Gaining or Losing Market Support? - Benzinga
Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England - Technology Networks
Revvity Stock Tumbles Despite Expanding Genomics England Alliance - MSN
The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years - Yahoo Finance
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - BioSpace
Revvity Expands Alliance with Genomics England -March 20, 2025 at 02:10 pm EDT - MarketScreener
Massive Breakthrough: Revvity's 100K Newborn Genetic Screening Program Targets 200 Rare Diseases - StockTitan
May 16th Options Now Available For Revvity (RVTY) - Nasdaq
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Simply Wall St
Revvity Inc (RVTY) 財務データ
収益
当期純利益
現金流量
EPS
4.80%
1.42%
大文字化:
|
ボリューム (24 時間):